Novo is already using AI where the payoff is easy to see
The most interesting part of Novo Nordisk’s new partnership with Anthropic is not the promise that AI could one day help discover better medicines. Claude is already saving the company time inside its existing drug-development process.
Novo says it has used Claude to automate trial-report generation and reduce the creation of certain patient documentation from months to minutes. The partnership will now expand into research and development, where Novo plans to test Anthropic’s Claude Science tools against scientific problems, biological research and drug mechanisms.
That moves AI deeper into one of the most expensive and time-consuming parts of healthcare. Drug development involves enormous amounts of scientific literature, clinical data, documentation, software and regulatory work long before a medicine reaches patients. Removing friction from even a portion of that process can be valuable without AI ever discovering a drug on its own.
The first big win may simply be speed
Much of the excitement around AI and pharmaceuticals has focused on the idea of models designing new molecules or identifying drug targets. Those opportunities are real, but they are also difficult to prove and can take years to translate into approved medicines.
The nearer-term opportunity is less dramatic and potentially much easier to monetize. Researchers can use models to review scientific information, generate documentation, assist with software development, compare findings and work through complex biological questions faster than traditional workflows allow.
A company such as Novo does not need AI to replace its scientists. It needs the same scientists to move through more information, test ideas faster and spend less time on repetitive work.
That is a much more believable path toward productivity gains across the pharmaceutical industry.
Healthcare could become one of AI’s most valuable enterprise markets
Pharma has something many other industries do not: proprietary scientific data, highly specialized employees and development timelines where saving time can materially change project economics.
The companies best positioned to benefit may therefore be those that combine powerful general-purpose models with deep internal datasets and scientific expertise. Novo brings decades of drug-development knowledge and clinical information. Anthropic brings a frontier model capable of working across language, code and increasingly complex scientific reasoning.
Similar partnerships are likely to spread across the sector as drugmakers look for practical ways to improve R&D productivity rather than simply adding “AI” to investor presentations.
There are still limits. Scientific outputs need verification, patient data requires strict protection, and regulators will expect companies to demonstrate that AI-assisted processes remain reliable. Healthcare is not an industry where an impressive model response is enough.
But Novo’s experience with trial documentation gives this story something the AI-healthcare sector has often lacked: a measurable use case already working inside a major pharmaceutical company.
The next phase of AI in healthcare may not begin with a machine inventing the next blockbuster drug. It may start by making the people already developing those drugs dramatically faster at their jobs.
Explore More Stories in Health
Disclaimer
Wall Street Access is an independent financial publisher. Wall Street Access is not a financial advisor. No company mentioned has compensated Wall Street Access for the preparation, publication or distribution of this article. This content is provided for informational and educational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Investing involves risk, including the possible loss of principal.
Prices, market capitalizations, financial figures and other market data are based on information available as of the date and time of publication and may change without notice. Information is drawn from public sources believed to be reliable but is not guaranteed to be complete or accurate. Opinions and expectations expressed are our own and may change as new information becomes available.
Readers should conduct their own due diligence and contact a licensed financial professional before making any investment decision. Past performance does not guarantee future results. Any material ownership interest or conflict of interest, where applicable, will be disclosed separately.
